Company Overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Why Investors Should Care
Net profit has compounded at 31.6% per year over the last five years.
Revenue has grown at a 367.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $376.07M (+91.3% YoY); net profit $-16.14M.
- Trailing 12 Months Year-on-year growth — revenue +60.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 367.3%, profit CAGR 31.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 367.27% |
| 1 Year: | 60.10% |
Compounded Profit Growth
| 5 Years: | 31.61% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +68.62% |
| 6 Months: | -5.00% |
| 3 Months: | +11.15% |
| 1 Month: | +9.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 367.3% over 5 years.
- Profit CAGR of 31.6% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARQT Arcutis Biotherapeutics, Inc. R2K | 26.81 | -1,340.50 | $3.35B | 0.00% | -4.03% | -1.43% | 367.27% | 31.61% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 2.78M | 5.19M | 38.11M | 49.57M | 30.86M | 44.76M | 65.85M | 81.50M | 99.22M | 129.50M | 105.40M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.83M | 7.49M | 8.69M | 11.69M | 9.78M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.02M | 74.01M | 90.53M | 117.81M | 95.61M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.55M | 88.62M | 82.01M | 99.43M | 104.70M |
| Operating Income | -6.95M | -8.54M | -14.65M | - | -28.65M | -35.63M | -38.30M | - | -36.09M | -42.08M | -57.08M | -62.63M | -65.83M | -104.75M | -76.27M | -66.76M | -36.90M | -31.62M | -50.08M | -39.07M | -24.53M | -14.61M | 8.53M | 18.39M | -9.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.82M | -11.95M | 11.12M | 21.43M | -6.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98M | 3.03M | 3.07M | 3.00M | 4.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.78M | -15.54M | 7.49M | 17.86M | -11.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 279.00K | 342.00K | 80.00K | 470.00K | 93.00K |
| Net Income | -6.66M | -8.29M | -14.48M | -12.57M | -28.01M | -35.41M | -38.20M | -34.05M | -36.04M | -42.01M | -56.98M | -64.32M | -67.41M | -107.71M | -80.10M | -70.99M | -44.77M | -35.38M | -52.33M | -41.54M | -25.06M | -15.89M | 7.41M | 17.39M | -11.29M |
| Diluted EPS | - | - | - | - | - | -0.94 | -1.01 | - | -0.76 | -0.84 | -1.14 | -1.27 | -1.31 | -1.89 | -1.31 | -1.16 | -0.73 | -0.32 | -0.42 | -0.33 | -0.20 | -0.13 | 0.06 | 0.13 | -0.09 |
| R&D Expense | 6.20M | 7.21M | 12.35M | - | 25.18M | 30.01M | 32.74M | - | 21.63M | 30.77M | 40.60M | 40.62M | 38.20M | 69.73M | 35.34M | 25.22M | 26.24M | 23.14M | 19.30M | 19.50M | 17.54M | 19.45M | 19.60M | - | 30.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | - | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | - | - | - | - | 754.00K | 4.99M | 19.13M | 36.70M |
| Gross Profit | - | - | - | - | 2.93M | 54.62M | 177.41M | 339.38M |
| Operating Expenses | - | - | - | - | 304.56M | 295.72M | 305.81M | 351.60M |
| Operating Income | -19.73M | -43.13M | -136.65M | - | -301.63M | -241.10M | -128.40M | -12.23M |
| EBITDA | - | - | - | - | -294.87M | -228.56M | -110.27M | 1.78M |
| Interest Expense | - | - | - | - | 15.65M | 29.71M | 27.17M | 12.08M |
| Pretax Income | - | - | - | - | -311.46M | -259.03M | -139.39M | -14.97M |
| Tax Provision | - | - | - | - | 0 | 3.11M | 647.00K | 1.17M |
| Net Income | -19.25M | -42.00M | -135.68M | - | -311.46M | -262.14M | -140.04M | -16.14M |
| Diluted EPS | - | -22.78 | -3.80 | - | -5.66 | -3.78 | -1.16 | -0.13 |
| R&D Expense | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 107.01M | 298.27M | - | 449.27M | 341.37M | 348.89M | 432.97M |
| Current Assets | - | - | - | - | - | 437.41M | 330.43M | 335.82M | 411.23M |
| Cash & Equivalents | - | - | 63.34M | 65.08M | - | 53.64M | 88.40M | 71.33M | 42.91M |
| Inventory | - | - | - | - | - | 7.51M | 13.13M | 14.53M | 22.63M |
| Receivables | - | - | - | - | - | 8.46M | 25.81M | 73.07M | 146.23M |
| Total Liabilities | - | - | 5.55M | 27.65M | - | 239.69M | 252.70M | 191.35M | 243.49M |
| Current Liabilities | - | - | 5.24M | 22.60M | - | 37.81M | 46.67M | 81.01M | 129.84M |
| Long Term Debt | - | - | - | 0 | - | 197.77M | 201.80M | 107.20M | 107.96M |
| Total Debt | - | - | - | - | - | 202.54M | 205.92M | 109.77M | 114.22M |
| Total Equity | -4.99M | -23.99M | -65.03M | 270.62M | - | 209.58M | 88.67M | 157.54M | 189.48M |
| Shares Outstanding | - | - | - | - | - | 61.04M | 96.79M | 117.85M | 123.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.09M | -42.84M | -113.03M | - | -257.71M | -247.06M | -112.16M | -5.62M |
| Investing Cash Flow | -11.53M | -26.32M | -181.82M | - | -87.20M | 180.23M | 28.82M | -30.25M |
| Financing Cash Flow | 61.59M | 93.10M | 298.14M | - | 301.80M | 101.32M | 66.20M | 6.97M |
| Capital Expenditure | -0 | -295.00K | -321.00K | - | -23.28M | -428.00K | -5.14M | -10.69M |
| Free Cash Flow | -14.09M | -43.13M | -113.35M | - | -281.00M | -247.49M | -117.30M | -16.31M |
| Net Change in Cash | - | - | - | - | -43.12M | 34.50M | -17.14M | -28.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 79.5% | 91.6% | 90.3% | 90.2% |
| Operating Margin % | - | - | - | - | -8,183.0% | -404.5% | -65.3% | -3.3% |
| Net Margin % | - | - | - | - | -8,449.8% | -439.8% | -71.3% | -4.3% |
| ROE % | 80.3% | 64.6% | -50.1% | - | -148.6% | -295.6% | -88.9% | -8.5% |
| ROCE % | - | -42.4% | -49.6% | - | -73.3% | -81.8% | -47.9% | -4.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.86% | 12.33M | $312.98M |
| 2 | Frazier Life Sciences Management, L.P. | 7.89% | 9.87M | $250.71M |
| 3 | Blackrock Inc. | 7.36% | 9.20M | $233.60M |
| 4 | Rubric Capital Management LP | 6.61% | 8.27M | $210.02M |
| 5 | State Street Corporation | 5.03% | 6.30M | $159.86M |
| 6 | Polar Capital Holdings PLC | 4.53% | 5.67M | $143.88M |
| 7 | Jennison Associates LLC | 3.98% | 4.98M | $126.46M |
| 8 | Vanguard Capital Management LLC | 3.89% | 4.87M | $123.69M |
| 9 | Gilder Gagnon Howe & Co LLC | 3.44% | 4.30M | $109.28M |
| 10 | Morgan Stanley | 3.37% | 4.22M | $107.12M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARQT
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-disease drugmaker to expand the use of its key cream, Zorvye.
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study1 million…
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the g…
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasisConnects eligible individuals with independent, board-certified derm…
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restriction…
ARQT — Frequently Asked Questions
What is the current share price of Arcutis Biotherapeutics, Inc. (ARQT)?
As of 2026-07-14 21:23 PDT, Arcutis Biotherapeutics, Inc. (ARQT) trades at $26.81 on NasdaqGS. Its 52-week range is $14.12 to $31.20.
What is the market capitalisation of ARQT?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $3.35B on NasdaqGS.
What is the P/E ratio of ARQT?
ARQT trades at a trailing price-to-earnings (P/E) ratio of -1,340.50. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 16.07.
What is the return on equity (ROE) of ARQT?
ARQT has a return on equity (ROE) of -1.43%. Its return on capital employed (ROCE) is -4.03%.
Is ARQT a good stock to buy?
This page provides a data-driven analysis of Arcutis Biotherapeutics, Inc. (ARQT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.